Scientists Discover New Compounds That Block Key Thyroid Hormone Enzyme
Researchers identified selective inhibitors of DIO2, a crucial enzyme that activates thyroid hormones in tissues throughout the body.
Summary
Scientists discovered new compounds that selectively block DIO2, a key enzyme responsible for converting inactive thyroid hormone T4 into active T3 in tissues. Using advanced screening of nearly 60,000 compounds, researchers identified 17 potent inhibitors, including FDA-approved drugs like racecadotril and ibrutinib. DIO2 is crucial for local thyroid hormone activation in various tissues, affecting metabolism, development, and tissue regeneration. These findings provide new tools for studying thyroid hormone function and may help identify medications that inadvertently disrupt thyroid signaling, potentially impacting metabolic health and longevity.
Detailed Summary
Thyroid hormones play a fundamental role in metabolism, energy production, and cellular function throughout the body. The enzyme DIO2 is particularly important because it converts inactive thyroid hormone T4 into active T3 directly within tissues, ensuring proper local hormone signaling that affects everything from brain function to metabolic rate.
Researchers screened nearly 60,000 chemical compounds using a sophisticated high-throughput testing system to identify substances that specifically inhibit DIO2. They used human cells engineered to produce large amounts of DIO2 enzyme and developed a colorimetric assay to measure enzyme activity without radioactive materials.
The screening identified 356 initial hits, which were narrowed down to 17 potent inhibitors after validation testing. Six compounds showed selective DIO2 inhibition, including two FDA-approved drugs: racecadotril (used for diarrhea) and ibrutinib (a cancer medication). The researchers also discovered that fluazinam, a common fungicide, inhibits multiple deiodinase enzymes.
These findings have significant implications for health optimization and longevity research. The identified compounds provide new research tools for studying how local thyroid hormone regulation affects aging processes, metabolic function, and tissue regeneration. More importantly, the discovery that existing medications can interfere with thyroid hormone activation suggests the need for closer monitoring of thyroid function in patients taking these drugs.
While this research provides valuable insights into thyroid hormone regulation, the studies were conducted in laboratory settings using isolated enzymes. Further research is needed to understand how these inhibitors affect thyroid function in living organisms and whether the concentrations used in the lab are relevant to real-world exposure levels.
Key Findings
- Scientists identified 17 potent inhibitors of DIO2, the key enzyme that activates thyroid hormones in tissues
- Two FDA-approved drugs (racecadotril and ibrutinib) unexpectedly block thyroid hormone activation
- The fungicide fluazinam inhibits multiple thyroid hormone enzymes, raising environmental health concerns
- New screening method enables rapid testing of compounds for thyroid hormone disruption
- Selective DIO2 inhibitors could serve as research tools for studying metabolism and aging processes
Methodology
Researchers used human cells engineered to overproduce DIO2 enzyme and developed a non-radioactive colorimetric assay. They screened 59,928 compounds from eight comprehensive libraries at 10 µM concentration, followed by validation screens and selectivity testing.
Study Limitations
Studies were conducted in isolated enzyme systems rather than living organisms. The clinical relevance of the inhibitor concentrations used in laboratory testing remains unclear, and long-term effects on thyroid function are unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.